We recently reported that a DNA plasmid coding p62-SQSTM1 acts as an effective anti tumor vaccine against both transplantable mouse tumors and canine spontaneous mammary neoplasms. Here we report the unexpected finding that intramuscular delivery of p62 DNA exerts a powerful anti-osteoporotic activity in a mouse model of inflammatory bone loss (i.e, ovariectomy) by combining bone-sparing and osteo-synthetic effects. Notably, the suppression of osteoporosis by p62DNA was associated with a sharp down-regulation of master inflammatory cytokines, and up-regulation of endogenous p62 protein by bone-marrow stromal cells. The present data provide a solid rational to apply p62 DNA vaccine as a safe, new therapeutic for treatment of inflammatory related bone loss diseases.
Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent
SABBIETI, Maria Giovanna;AGAS, DIMITRIOS;CAPITANI, MELANIA;MARCHETTI, Luigi;CONCETTI, Antonio;VULLO, CECILIA;CATONE, Giuseppe;VENANZI, Franco
2015-01-01
Abstract
We recently reported that a DNA plasmid coding p62-SQSTM1 acts as an effective anti tumor vaccine against both transplantable mouse tumors and canine spontaneous mammary neoplasms. Here we report the unexpected finding that intramuscular delivery of p62 DNA exerts a powerful anti-osteoporotic activity in a mouse model of inflammatory bone loss (i.e, ovariectomy) by combining bone-sparing and osteo-synthetic effects. Notably, the suppression of osteoporosis by p62DNA was associated with a sharp down-regulation of master inflammatory cytokines, and up-regulation of endogenous p62 protein by bone-marrow stromal cells. The present data provide a solid rational to apply p62 DNA vaccine as a safe, new therapeutic for treatment of inflammatory related bone loss diseases.File | Dimensione | Formato | |
---|---|---|---|
Oncotarget Supp. Mat.pdf
accesso aperto
Descrizione: Supplementary Materials
Tipologia:
Versione Editoriale
Licenza:
PUBBLICO - Creative Commons
Dimensione
1.3 MB
Formato
Adobe PDF
|
1.3 MB | Adobe PDF | Visualizza/Apri |
Oncotarget 2015 p3590.pdf
accesso aperto
Tipologia:
Versione Editoriale
Licenza:
PUBBLICO - Creative Commons
Dimensione
6.83 MB
Formato
Adobe PDF
|
6.83 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.